Abstract:
3-(.beta.-aminoethylidene)-6-(.alpha.-hydroxyethyl)-7-oxo-4-oxaazabicyclo[3.2.0]heptane-2-carboxylic acid having the structural formula: ##STR1## and the pharmaceutically acceptable salt, ester and amide derivatives thereof are disclosed to be useful as antibiotics. Also disclosed are processes for the preparation of such compounds; pharmaceutical compositions comprising such compounds; and methods of treatment comprising administering such compounds and compositions when an antibiotic effect is indicated.
Abstract:
Use of the 2-amino-2,4,4-trimethylpentane salt of clavulanic acid as an intermediate in the production of pharmaceutically acceptable salts of clavulanic acid.
Abstract:
The present invention relates to compounds that are substrates for an enzyme, and upon reaction with the enzyme provide a detectable response, such as an optically detectable response. In particular, the compounds have utility in detecting the presence of a β-lactamase in a sample. In addition to the compounds, methods are disclosed for analyzing a sample for the presence of a β-lactmase, for example, as an indicator of expression of a nucleic acid sequence including a sequence coding for a β-lactmase. Kits are disclosed that include the disclosed compounds and additional components, for example, cells, antibodies, a β-lactmase or instructions for using the components in an assay.
Abstract:
A process for the preparation of a substituted C-2 β-lactam comprises incubating a 2-substituted 3-aminocarboxylic acid with a β-lactam synthetase under conditions such that the 2-substituted 3-aminocarboxylic acid is cyclised to produce a substituted C-2 β-lactam. The process can be used to produce an antibiotic or β-lactamase inhibitor.
Abstract:
The present invention is based on the discovery that certain 3-(substituted methyl)-4-oxa-1-azabicyclo[3.2.0]heptan-7-one derivatives of formula I or a pharmaceutically acceptable salt thereof are useful as antitumor agents against sensitive and resistant tumor cells. ##STR1## Wherein X is NH or O, and R is defined in the specification.
Abstract:
Improved methods for the preparation of clavams by fermentation of a clavam-producing organism in a suitable medium wherein the ammonium levels are kept low so as to avoid repression of enzymes, particularly urease, are disclosed.
Abstract:
A process for purification of crude clavulanic acid and its subsequent conversion to its potassium salt. A crude clavulanic acid extract is contacted in an organic solvent with an alkylenediamine of the formula II ##STR1## wherein the substituents R.sub.1, R.sub.2, R.sub.3 and R.sub.4 each individually denote a hydrogen atom, or a straight chain or a branched chain alkyl group having 1 to 8 carbon atoms, R.sub.5 denotes a hydrogen atom, and n denotes an integer 1. The thus obtained alkylenediammonium diclavulanates of the formula I are isolated ##STR2## wherein the substituents R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 and n have the meanings as defined at formula II. Salts of the alkylenediammonium diclavulanate of the formula I are converted with potassium 2-ethyl-hexanoate in isopropanol into potassium salt of clavulanic acid.
Abstract:
A di-clavulanate salt derived from clavulanic acid and a diamino ether of the formula ##STR1## wherein R.sup.1 is an alkylene group, optionally having one or more inert substituents: and each of R.sup.2 and R.sup.3 is a hydrogen atom or an alkyl group, optionally having one or more inert substituents, or R.sup.2 and R.sup.3 together complete a heterocyclic ring having four to seven carbon atoms, again optionally having one or more inert substituents. A process for preparing the clavulanic acid salt includes the steps of preparing a substantially water free solution of clavulanic acid, or a salt thereof, in an organic solvent which solution is at a maintained temperature of 0.degree. to 15.degree. C. and then reacting the clavulanic acid, or salt thereof, with diamino ether in the organic solvent.
Abstract:
A process is disclosed for preparing potassium clavulanate in the form of crystalline rosettes by addition of a solution of clavulanate ions to a solution of potassium ions in a non-solvent for potassium clavulanate.
Abstract:
Potassium clavulanate exists in a novel crystalline habit, namely in the form of rosettes, having improved processing properties. The novel form may, for example, be obtained by crystallization or recrystallization using inverse precipitation, preferably at 8.degree.-15.degree. C.